The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions

Lignende værker

• Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
  af: Tanaka Nobumichi, et al.
  Udgivet: (2013-01-01)
• Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
  af: Tanaka, Nobumichi, et al.
  Udgivet: (2013)
• Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
  af: Tanaka Nobumichi, et al.
  Udgivet: (2012-09-01)
• Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
  af: Tanaka, Nobumichi, et al.
  Udgivet: (2012)
• Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
  af: Tanaka, Nobumichi, et al.
  Udgivet: (2014)